Teresa Velazquez-Caballero

CP 41013 Sevilla
Sevilla, AN 41013, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 65 publications

Pediatric B-Cell Acute Lymphoblastic Leukemia: Comprehensive Genomic Characterization Including SNP-Array and Analysis of Relapse Risk.

Pediatric B-Cell Acute Lymphoblastic Leukemia: Comprehensive Genomic Characterization Including SNP-Array and Analysis of Relapse Risk.

Journal: Cancers

Published: July 01, 2026

Impact of inotuzumab ozogamicin as bridging therapy and tumor burden in CAR-T therapy for B-acute lymphoblastic leukemia.

Impact of inotuzumab ozogamicin as bridging therapy and tumor burden in CAR-T therapy for B-acute lymphoblastic leukemia.

Journal: Frontiers in immunology

Published: October 15, 2025

Temporal dynamics of substance P and its association with cytokine release syndrome after CD19 CAR-T therapy in pediatric B-ALL.

Temporal dynamics of substance P and its association with cytokine release syndrome after CD19 CAR-T therapy in pediatric B-ALL.

Journal: Stem cell research & therapy

Published: October 14, 2025

Phase I/II Trials of Donor Regulatory T Cells for the Treatment of Steroid-Refractory Chronic Graft versus Host Disease.

Phase I/II Trials of Donor Regulatory T Cells for the Treatment of Steroid-Refractory Chronic Graft versus Host Disease.

Journal: Blood advances

Published: August 05, 2025

BCL2-overexpression in donor lymphocytes reduces the risk of graft-versus-host disease.

BCL2-overexpression in donor lymphocytes reduces the risk of graft-versus-host disease.

Journal: Blood advances

Published: July 08, 2025

BCL2 overexpression in donor lymphocytes reduces the risk of graft-versus-host disease.

BCL2 overexpression in donor lymphocytes reduces the risk of graft-versus-host disease.

Journal: Blood advances

Published: July 08, 2025

Frontline allo-SCT in MRD-negative, intermediate-risk AML.

Frontline allo-SCT in MRD-negative, intermediate-risk AML.

Journal: Blood advances

Published: March 24, 2025

Ixazomib decreases the risk of chronic graft-versus-host disease: identification of cGVHD biomarkers.

Ixazomib decreases the risk of chronic graft-versus-host disease: identification of cGVHD biomarkers.

Journal: Blood advances

Published: February 25, 2025

Computational flow cytometry immunophenotyping at diagnosis is unable to predict relapse in childhood B-cell Acute Lymphoblastic Leukemia.

Computational flow cytometry immunophenotyping at diagnosis is unable to predict relapse in childhood B-cell Acute Lymphoblastic Leukemia.

Journal: Computers in biology and medicine

Published: November 20, 2024

GvHD prophylaxis with tacrolimus, sirolimus, and mycophenolate mofetil after reduced intensity conditioning hematopoietic stem cell allogeneic transplantation.

GvHD prophylaxis with tacrolimus, sirolimus, and mycophenolate mofetil after reduced intensity conditioning hematopoietic stem cell allogeneic transplantation.

Journal: Bone marrow transplantation

Published: October 21, 2024

Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1: the impact of manufacturing procedure on CAR T-cell features.

Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1: the impact of manufacturing procedure on CAR T-cell features.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: August 09, 2024

A phase 2, multicenter, clinical trial of CPX-351 in older patients with secondary or high-risk acute myeloid leukemia: PETHEMA-LAMVYX.

A phase 2, multicenter, clinical trial of CPX-351 in older patients with secondary or high-risk acute myeloid leukemia: PETHEMA-LAMVYX.

Journal: Cancer

Published: August 02, 2024

Showing 1-12 of 65

Last Updated: 09/26/2026